David A. Siegel Lava Therapeutics Nv Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Two Sigma Advisers, LP holds 26,900 shares of LVTX stock, worth $27,707. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,900
Previous 31,700
15.14%
Holding current value
$27,707
Previous $57,000
22.81%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LVTX
# of Institutions
28Shares Held
3.61MCall Options Held
32.9KPut Options Held
500-
Redmile Group, LLC San Francisco, CA2.07MShares$2.14 Million0.23% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$795,0300.53% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3146KShares$150,8500.04% of portfolio
-
Two Sigma Investments, LP New York, NY103KShares$105,8480.0% of portfolio
-
Pathway Financial Advisors LLC103KShares$105,5750.04% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $26.6M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...